Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2020

Open Access 01-12-2020 | Antiarrhythmic Drugs | Case report

Refractoriness to subcutaneous implantable cardioverter defibrillator after frequent therapies for ventricular fibrillation storms in a Brugada syndrome case

Authors: Yasuhisa Nakao, Kazuyoshi Suenari, Kohei Yamashiro, Hiroshi Nakagawa, Nobuo Shiode

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Login to get access

Abstract

Background

The subcutaneous implantable cardioverter defibrillator (S-ICD) is an alternative to the transvenous implantable cardioverter defibrillator for the prevention of sudden cardiac death. Here, we report a rare case of refractoriness to an S-ICD after frequent therapies for ventricular fibrillation (VF) storms.

Case presentation

A 24-year-old man underwent a bout of syncope with vomiting and incontinence at home. He was brought to the emergency room and was witnessed to spontaneously go into VF successfully converted by external defibrillation. Previously, he was diagnosed with a type I Brugada electrocardiogram pattern by a pilsicainide administration test in another hospital. Although he had a family history of sudden cardiac death in 3 relatives, including his brother, he was followed closely without any therapies because he had never had an episode of syncope. He was implanted with an S-ICD without any trouble. Seven months later, frequent S-ICD shocks for VF storms occurred. His VF was controlled by using intravenous amiodarone, which was converted to an oral preparation. However, his VF recurred after another 2 months. The analysis of his S-ICD data revealed that 4 consecutive shock deliveries could not terminate his VF and the final shock delivered could fortunately terminate it because of a high defibrillation threshold test (DFT) due to an increasing shock impedance (64 to 90 Ω). First, we performed an epicardial Brugada syndrome ablation and subsequently replaced and repositioned the S-ICD lead from a left to a right parasternal site. After the re-implantation of the S-ICD, the DFT test improved to within normal range. According to the pathological analysis, infiltration of inflammatory cells and extensive fibrosis were confirmed in the subcutaneous tissue around the shock lead and S-ICD body.

Conclusion

Frequent S-ICD shocks for VF storms might cause various pathological changes around the device and lead to a high DFT.
Literature
1.
go back to reference Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, Maass AH, de Groot JR, van Oostrom AJ, Theuns DA, Jordaens LJ, Wilde AA, Knops RE. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol. 2012;60(19):1933–9.CrossRef Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, Maass AH, de Groot JR, van Oostrom AJ, Theuns DA, Jordaens LJ, Wilde AA, Knops RE. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol. 2012;60(19):1933–9.CrossRef
2.
go back to reference Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in may 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932–63.CrossRef Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in may 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932–63.CrossRef
3.
go back to reference Boersma L, Barr C, Knops R, Theuns D, Eckardt L, Neuzil P, Scholten M, Hood M, Kuschyk J, Jones P, et al. Implant and midterm outcomes of the subcutaneous implantable Cardioverter-defibrillator registry: the EFFORTLESS study. J Am Coll Cardiol. 2017;70(7):830–41.CrossRef Boersma L, Barr C, Knops R, Theuns D, Eckardt L, Neuzil P, Scholten M, Hood M, Kuschyk J, Jones P, et al. Implant and midterm outcomes of the subcutaneous implantable Cardioverter-defibrillator registry: the EFFORTLESS study. J Am Coll Cardiol. 2017;70(7):830–41.CrossRef
4.
go back to reference Amin AK, Gold MR, Burke MC, Knight BP, Rajjoub MR, Duffy E, Husby M, Stahl WK, Weiss R. Factors associated with high-voltage impedance and subcutaneous implantable defibrillator ventricular fibrillation conversion success. Circ Arrhythm Electrophysiol. 2019;12(4):e006665.CrossRef Amin AK, Gold MR, Burke MC, Knight BP, Rajjoub MR, Duffy E, Husby M, Stahl WK, Weiss R. Factors associated with high-voltage impedance and subcutaneous implantable defibrillator ventricular fibrillation conversion success. Circ Arrhythm Electrophysiol. 2019;12(4):e006665.CrossRef
5.
go back to reference Frankel DS, Burke MC, Callans DJ, Stivland TM, Duffy E, Epstein AE. Impact of body mass index on safety and efficacy of the subcutaneous implantable Cardioverter-defibrillator. JACC Clin Electrophysiol. 2018;4(5):652–9.CrossRef Frankel DS, Burke MC, Callans DJ, Stivland TM, Duffy E, Epstein AE. Impact of body mass index on safety and efficacy of the subcutaneous implantable Cardioverter-defibrillator. JACC Clin Electrophysiol. 2018;4(5):652–9.CrossRef
6.
go back to reference Saltzman HE, Angel B, Overcash J, Kutalek S. Increased shock impedance is associated with failed subcutaneous implantable cardioverter defibrillator defibrillation threthold testing. J Am Coll Cardiol. 2017;69(11 Supplement):351.CrossRef Saltzman HE, Angel B, Overcash J, Kutalek S. Increased shock impedance is associated with failed subcutaneous implantable cardioverter defibrillator defibrillation threthold testing. J Am Coll Cardiol. 2017;69(11 Supplement):351.CrossRef
7.
go back to reference Heist EK, Belalcazar A, Stahl W, Brouwer TF, Knops RE. Determinants of subcutaneous implantable Cardioverter-defibrillator efficacy: a computer modeling study. JACC Clin Electrophysiol. 2017;3(4):405–14.CrossRef Heist EK, Belalcazar A, Stahl W, Brouwer TF, Knops RE. Determinants of subcutaneous implantable Cardioverter-defibrillator efficacy: a computer modeling study. JACC Clin Electrophysiol. 2017;3(4):405–14.CrossRef
8.
go back to reference Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110(13):1731–7.CrossRef Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110(13):1731–7.CrossRef
9.
go back to reference Murakami M, Nakamura K, Kusano KF, Morita H, Nakagawa K, Tanaka M, Tada T, Toh N, Nishii N, Nagase S, et al. Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation. J Cardiovasc Pharmacol. 2010;56(4):389–95.CrossRef Murakami M, Nakamura K, Kusano KF, Morita H, Nakagawa K, Tanaka M, Tada T, Toh N, Nishii N, Nagase S, et al. Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation. J Cardiovasc Pharmacol. 2010;56(4):389–95.CrossRef
10.
go back to reference Brodie OT, Michowitz Y, Belhassen B. Pharmacological therapy in Brugada syndrome. Arrhythm Electrophysiol Rev. 2018;7(2):135–42.CrossRef Brodie OT, Michowitz Y, Belhassen B. Pharmacological therapy in Brugada syndrome. Arrhythm Electrophysiol Rev. 2018;7(2):135–42.CrossRef
11.
go back to reference Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, Connolly SJ. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006;114(2):104–9.CrossRef Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, Connolly SJ. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006;114(2):104–9.CrossRef
12.
go back to reference Wakabayashi Y, Mitsuhashi T, Fujita H, Momomura SI. Usefulness of lead repositioning from left to right sternal border for a patient with subcutaneous implantable cardioverter defibrillator showing high defibrillation threshold. J Arrhythm. 2019;35(1):133–5.CrossRef Wakabayashi Y, Mitsuhashi T, Fujita H, Momomura SI. Usefulness of lead repositioning from left to right sternal border for a patient with subcutaneous implantable cardioverter defibrillator showing high defibrillation threshold. J Arrhythm. 2019;35(1):133–5.CrossRef
Metadata
Title
Refractoriness to subcutaneous implantable cardioverter defibrillator after frequent therapies for ventricular fibrillation storms in a Brugada syndrome case
Authors
Yasuhisa Nakao
Kazuyoshi Suenari
Kohei Yamashiro
Hiroshi Nakagawa
Nobuo Shiode
Publication date
01-12-2020

Other articles of this Issue 1/2020

BMC Cardiovascular Disorders 1/2020 Go to the issue